XL413·HCl | Cdc7 inhibitor/CRISPR enhancer
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $225.00 |
XL413 (2062200-97-7) is a potent (IC50 = 4.8 nM) ATP-competitive inhibitor of the important DNA replication initiation kinase Cdc7 (DDK).1 It increases the efficiency of homology directed DNA repair in CRISPR-Cas9 gene editing.2 XL413 acted synergistically with other chemotherapy agents in various cancer models.3-5
References/Citations:
- Koltun et al. (2012), Discovery of XL413, a potent and selective CDC7 inhibitor; Bioorg .Med. Chem. Lett. 22 3727
- Wienert et al. (2020), Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair; Nat. Commun. 11 2109
- Deng et al. (2023), Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening; Cell Death Discov. 9 40
- Zhang et al. (2023), DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy; Int. J. Biol. Sci. 19 3427
- Li et al. (2024), Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer; Nat. Commun. 39 10185
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
XL413 (2062200-97-7) is a potent (IC50 = 4.8 nM) ATP-competitive inhibitor of the important DNA replication initiation kinase Cdc7 (DDK).1 It increases the efficiency of homology directed DNA repair in CRISPR-Cas9 gene editing.2 XL413 acted synergistically with other chemotherapy agents in various cancer models.3-5
References/Citations:
- Koltun et al. (2012), Discovery of XL413, a potent and selective CDC7 inhibitor; Bioorg .Med. Chem. Lett. 22 3727
- Wienert et al. (2020), Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair; Nat. Commun. 11 2109
- Deng et al. (2023), Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening; Cell Death Discov. 9 40
- Zhang et al. (2023), DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy; Int. J. Biol. Sci. 19 3427
- Li et al. (2024), Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer; Nat. Commun. 39 10185
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass